Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:1 Issue:5 Number:188 ISSN#:2563-5476
ACE Report #4415
Ace Report Cover Metabolic Disorders

Denosumab increases bone mass but does not reduce fracture risk compared to alendronate

Study Type:Meta-analysis/Systematic Review
OE Level Evidence:1
Journal Level of Evidence:N/A

Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis

Int J Clin Pract. 2012 Apr;66(4):399-408. doi: 10.1111/j.1742-1241.2011.02806.x. Epub 2012 Feb 7

Contributing Authors: T Lin C Wang XZ Cai X Zhao MM Shi ZM Ying FZ Yuan C Guo SG Yan

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


4 randomised control trials were included in this meta-analysis, to compare the effectiveness of 60mg Denosumab subcutaneously per 6 months (Den) to 70mg Alendronate orally per week (Aln) in the treatment of osteoporosis in postmenopausal women. A total of 1952 women were identified that were followed-up for one year. The primary outcomes were the incidence of clinical fractures and bone mineral d...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.